The expression of human chorionic gonadotropin/human luteinizing hormone receptors in human gestational trophoblastic neoplasms.
Normal human placental trophoblasts have recently been shown to contain receptors for hCG/hLH. The present studies investigated the expression of these receptors in hyperplastic and anaplastic trophoblasts in gestational trophoblastic neoplasms. The results demonstrated that both hydatidiform moles and choriocarcinomas contained receptor messenger RNA (mRNA) and receptor protein. A variety of nontrophoblast tumors, on the other hand, contained neither receptor mRNA nor receptor protein. Choriocarcinomas contained more receptor mRNA and receptor protein than hydatidiform moles which in turn contained more than normal human placenta. Midluteal phase human corpus luteum contained more receptor mRNA than normal human placenta and about the same as choriocarcinomas. The hyperplastic and anaplastic trophoblasts in hydatidiform moles and choriocarcinomas contained more receptor immunostaining than the normal trophoblasts in the same tissue or those from normal placentas from about the same gestational age. The receptor immunostaining increased as the degree of trophoblast hyperplasia increased in hydatidiform moles. Anaplastic trophoblasts of choriocarcinomas contained a similar amount of receptor immunostaining as severely hyperplastic trophoblasts of hydatidiform moles. Invading anaplastic trophoblasts of choriocarcinoma contained greater amount of receptor immunostaining than the surrounding endometrial stromal and myometrial smooth muscle cells. In summary, this is the first study to our knowledge demonstrating the expression of hCG/hLH receptor gene in gestational trophoblastic neoplasms. The increased receptor expression in these neoplasms suggests that hCG, via its receptors, could play a fundamental and previously unsuspected autocrine role in the regulation of trophoblast transformation, growth, invasion, and high hCG secretion.
Lei
Z M
ZM
Department of Obstetrics and Gynecology, University of Louisville, School of Medicine, Kentucky 40292.
Rao
C V
CV
Ackerman
D M
DM
Day
T G
TG
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D002822:Choriocarcinoma / Q000235:genetics / Q000473:pathology*; D003338:Corpus Luteum / Q000166:cytology / Q000502:physiology; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000235:genetics / Q000473:pathology*; D008545:Melanoma / Q000235:genetics / Q000473:pathology; D009693:Nucleic Acid Hybridization; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000473:pathology; D010920:Placenta / Q000166:cytology / Q000502:physiology*; D011247:Pregnancy; D016372:RNA, Antisense; D012333:RNA, Messenger / Q000032:analysis* / Q000235:genetics; D011967:Receptors, Gonadotropin / Q000032:analysis* / Q000235:genetics; D011974:Receptors, LH / Q000032:analysis* / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology; D014158:Transcription, Genetic; D014594:Uterine Neoplasms / Q000235:genetics / Q000473:pathology*
D016372:RNA, Antisense; D012333:RNA, Messenger; D011967:Receptors, Gonadotropin; D011974:Receptors, LH